Type 1 vs. Type 2 Diabetes: Key Differences Explained

What causes each type?

Type 1 diabetes occurs when the immune system mistakenly attacks and destroys the beta cells in the pancreas — the cells that produce insulin. Without insulin, glucose cannot enter cells, and blood sugar rises to dangerous levels. The trigger for this autoimmune attack is not fully understood; genetic factors play a role, but most people diagnosed have no family history. Type 1 accounts for roughly 5–10% of all diabetes diagnoses 1Ref 1American Diabetes Association Professional Practice Committee (2024).2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024.Diagnostic criteria, prevalence of type 1 (~5–10%) vs type 2 (~90–95%), classification using antibody/C-peptide testing, LADA definition, and treatment approaches by type.

Type 2 diabetes develops through a different process. Cells in the muscles, liver, and fat tissue become resistant to insulin — they stop responding to it properly. The pancreas initially compensates by producing more insulin, but over years its capacity to do so gradually declines. Type 2 is strongly associated with excess body weight, physical inactivity, age, and genetic predisposition, but people who are lean and physically active can also develop it 1Ref 1American Diabetes Association Professional Practice Committee (2024).2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024.Diagnostic criteria, prevalence of type 1 (~5–10%) vs type 2 (~90–95%), classification using antibody/C-peptide testing, LADA definition, and treatment approaches by type.

Who gets type 1 vs. type 2?

Type 1 was historically called 'juvenile diabetes' because it commonly appears in children and young adults — but adults can and do develop it at any age. In fact, the majority of new type 1 diagnoses in absolute numbers occur in adults, not children.

Type 2 is far more common overall and accounts for roughly 90–95% of all diabetes diagnoses 1Ref 1American Diabetes Association Professional Practice Committee (2024).2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024.Diagnostic criteria, prevalence of type 1 (~5–10%) vs type 2 (~90–95%), classification using antibody/C-peptide testing, LADA definition, and treatment approaches by type. It becomes more prevalent with age, though rates among younger adults and adolescents have risen alongside increasing obesity rates.

There is also a slower-onset form of autoimmune diabetes called LADA (latent autoimmune diabetes in adults), which shares features of both types and is sometimes initially misclassified as type 2. Antibody testing helps distinguish it 1Ref 1American Diabetes Association Professional Practice Committee (2024).2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024.Diagnostic criteria, prevalence of type 1 (~5–10%) vs type 2 (~90–95%), classification using antibody/C-peptide testing, LADA definition, and treatment approaches by type2Ref 2American Diabetes Association Professional Practice Committee (2025).2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2025.Updated recommendations on CGM use in type 1 and type 2, GLP-1 agonist and SGLT2 inhibitor guidance, cardiovascular risk management in type 2, and integrated approach to distinguishing type 1 from type 2 in adults.

How is each type treated?

Type 1: Because the pancreas produces little to no insulin, insulin therapy is required from the moment of diagnosis — there is no alternative. Most people with type 1 use multiple daily injections of basal and prandial insulin or an insulin pump. Continuous glucose monitoring (CGM) has become central to type 1 management by providing real-time blood sugar data and reducing hypoglycemia risk 2Ref 2American Diabetes Association Professional Practice Committee (2025).2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2025.Updated recommendations on CGM use in type 1 and type 2, GLP-1 agonist and SGLT2 inhibitor guidance, cardiovascular risk management in type 2, and integrated approach to distinguishing type 1 from type 2 in adults.

Type 2: Treatment typically starts with lifestyle modification (diet, physical activity, and weight management), often combined with metformin. Over time, many people with type 2 need additional medications. GLP-1 receptor agonists and SGLT2 inhibitors are increasingly used early in treatment for their cardiovascular and kidney-protective benefits beyond glucose lowering 2Ref 2American Diabetes Association Professional Practice Committee (2025).2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2025.Updated recommendations on CGM use in type 1 and type 2, GLP-1 agonist and SGLT2 inhibitor guidance, cardiovascular risk management in type 2, and integrated approach to distinguishing type 1 from type 2 in adults. Insulin is sometimes added when other treatments are insufficient, but it is not always required — particularly in the earlier stages of the disease 1Ref 1American Diabetes Association Professional Practice Committee (2024).2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024.Diagnostic criteria, prevalence of type 1 (~5–10%) vs type 2 (~90–95%), classification using antibody/C-peptide testing, LADA definition, and treatment approaches by type.

Can type 2 diabetes be reversed?

Type 2 diabetes can go into remission — meaning blood sugar returns to a normal range without medication — in some people who achieve significant weight loss. This has been demonstrated most clearly after bariatric surgery and in structured low-calorie dietary programs. Remission is not guaranteed and does not mean the underlying susceptibility is gone; monitoring should continue.

Type 1 diabetes cannot go into remission through lifestyle changes because the underlying cause is autoimmune destruction of insulin-producing cells — not reversible through weight or diet.

Are the long-term complications the same?

Both types share the same spectrum of long-term complications when blood sugar is poorly controlled: damage to blood vessels (both large and small), nerves, kidneys, and eyes 1Ref 1American Diabetes Association Professional Practice Committee (2024).2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024.Diagnostic criteria, prevalence of type 1 (~5–10%) vs type 2 (~90–95%), classification using antibody/C-peptide testing, LADA definition, and treatment approaches by type. The mechanisms are similar — chronic high glucose is toxic to these tissues over time.

The primary differences are in timeline and baseline risk: people with type 1 may accumulate exposure over a longer lifetime if diagnosed young; people with type 2 often have additional cardiovascular risk factors (high blood pressure, elevated cholesterol) present at the time of diagnosis, requiring broader cardiovascular risk management 2Ref 2American Diabetes Association Professional Practice Committee (2025).2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2025.Updated recommendations on CGM use in type 1 and type 2, GLP-1 agonist and SGLT2 inhibitor guidance, cardiovascular risk management in type 2, and integrated approach to distinguishing type 1 from type 2 in adults.

How is the diagnosis confirmed and the type determined?

The diagnostic criteria for diabetes are the same regardless of type — fasting blood glucose, a two-hour oral glucose tolerance test, a random glucose with symptoms, or HbA1c 1Ref 1American Diabetes Association Professional Practice Committee (2024).2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024.Diagnostic criteria, prevalence of type 1 (~5–10%) vs type 2 (~90–95%), classification using antibody/C-peptide testing, LADA definition, and treatment approaches by type. An HbA1c of 6.5% or above on two separate tests is diagnostic.

Distinguishing type 1 from type 2 requires additional testing: antibody tests (GAD65, IA-2, ZnT8 antibodies confirm autoimmune origin) and C-peptide levels, which indicate how much insulin the pancreas is still making 1Ref 1American Diabetes Association Professional Practice Committee (2024).2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024.Diagnostic criteria, prevalence of type 1 (~5–10%) vs type 2 (~90–95%), classification using antibody/C-peptide testing, LADA definition, and treatment approaches by type2Ref 2American Diabetes Association Professional Practice Committee (2025).2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2025.Updated recommendations on CGM use in type 1 and type 2, GLP-1 agonist and SGLT2 inhibitor guidance, cardiovascular risk management in type 2, and integrated approach to distinguishing type 1 from type 2 in adults.

This distinction matters clinically — a person with type 1 or LADA misclassified as type 2 may be undertreated without insulin until the correct type is recognized.